Doxorubicin hydrochloride liposome

DRUG2 trials

Sponsors

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., Sichuan Baili Pharmaceutical Co., Ltd.

Conditions

Diffuse Large B-Cell LymphomaOvarian Cancer

Phase 1

Assess Bioequivalence of Two Formulations of Doxorubicin Hydrochloride Liposome in Female Patients With Ovarian Cancer

CompletedNCT02237690

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.Ovarian Cancer

Start: 2014-09-30End: 2016-08-31Updated: 2017-06-05

A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma

Not yet recruitingNCT07818499

Sichuan Baili Pharmaceutical Co., Ltd.Diffuse Large B-Cell Lymphoma

Start: 2026-09-01End: 2028-12-01Target: 204Updated: 2026-09-14